RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models

// Oi Kwan Wong 1,6 , Thomas-Toan Tran 1,3 , Wei-Hsien Ho 1,4 , Meritxell Galindo Casas 1,5 , Melinda Au 1,6 , Marjorie Bateman 1 , Kevin C. Lindquist 1 , Arvind Rajpal 1,2 , David L. Shelton 1 , Pavel Strop 1,2 and Shu-Hui Liu 1,7 1 Oncology RD antibody-drug conjugate; site-specific conjugation; non-small cell lung cancer; target therapy Received: June 26, 2018     Accepted: August 06, 2018     Published: September 11, 2018 Abstract Epidermal growth factor receptor (EGFR) is a clinically validated target and often overexpressed in some solid tumors. Both EGFR tyrosine kinase inhibitors and ligand-blocking antibodies have been approved for treatment of NSCLC, head and neck cancers and colorectal cancers. However, clinical response is limited and often accompanied by significant toxicities due to normal tissue expression. To improve the effectiveness of targeting EGFR while minimizing the toxicities on normal tissues, we developed a low-affinity anti-EGFR antibody drug conjugate (ADC), RN765C. Potent in vitro cytotoxicity of RN765C, with nanomolar to subnanomolar EC50, was observed on a panel of cancer cell lines expressing moderate to high level of EGFR. In contrast, RN765C was less effective in killing normal human keratinocytes, presumably due to its lower receptor expression. Mechanistically, RN765C has multiple modes of action: inducing payload mediated mitotic arrest and cell death, blocking EGFR pathway signal and mediating antibody dependent cell cytotoxicity. In preclinical studies, a single dose of RN765C at 1.5-3 mg/kg was generally sufficient to induce tumor regression in multiple cell line and patient-derived xenograft models, including those that are resistant to EGFR-directed tyrosine kinase inhibitors. Our data support further investigation of RN765C in the clinic to treat EGFR expressing solid tumors.